Reset filters
20 December 2024

Pulmonary arterial hypertension (PAH) is a chronic progressive exacerbation of cardiopulmonary vascular disease. The patients' exercise endurance decreased progressively and the survival rate was low. Current basic therapy and targeted drug therapy can improve the quality of life (QoL) of PAH patients, but the long-term efficacy and prognosis are not good.

Pulmonary Circulation
11 December 2024

Webinar presentations: Hispanic ethnicity and social determinants of health in pulmonary arterial hypertension; Sirtuin 3 and uncoupling protein2, the missing link between genetics, metabolism, and pulmonary arterial hypertension; Estrogen and portopulmonary hypertension: the Pulmonary Vascular Complications of Liver Disease Study; The right heart network and risk stratification in pulmonary arterial hypertension; Pulmonary hypertension caused by autocrine endothelial signaling
 

Members Only
10 December 2024

Pulmonary hypertension (PH) is a frequent complication of chronic lung disease (CLD). However, PH is difficult to diagnose early since accompanying symptoms overlap and are similar to those of the underlying CLD. In most cases the PH is mild to moderate and therefore physical signs may be absent or subtle.

Pulmonary Circulation
10 December 2024

Overnight inpatient monitoring is common following balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH). We describe our institutional experience in same-day discharge (SDD) after BPA. Across 78 BPA sessions, there were only 2 (2.6%) admissions for hemoptysis with no reperfusion lung injury or deaths at 30 days.

Pulmonary Circulation